ALK/ROS1/MET Mutations on Plasma ctDNA in Patients With NSCLC
NCT02946216 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200
Last updated 2016-10-27
Summary
The study aims to explore the prevalence of ALK/ROS1/MET mutations assessed with ctDNA samples in EGFR-wildtype NSCLC
Conditions
- Non-small Cell Lung Cancer Stage III
- Non-Small-Cell Lung Cancer Metastatic
- Adenocarcinoma of Lung
- EGFR Wildtype
Interventions
- GENETIC
-
ctDNA analysis
Sponsors & Collaborators
-
First People's Hospital of Hangzhou
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-11-30
- Primary Completion
- 2017-11-30
- Completion
- 2018-11-30
Countries
- China
Study Locations
More Related Trials
-
Multiplex Analysis of Circulating Tumor DNA
NCT03301961 ·Status: UNKNOWN
-
A Real-World Study of Treatment Patterns and Effectiveness in MET Mutation-Positive Advanced Lung Cancer
NCT06183762 ·Status: RECRUITING
-
Molecular Landscape Analysis and Clinical Implications for NSCLC Patients With Rare Mutations
NCT05701787 ·Status: RECRUITING
-
Analysis of Driver Gene Mutation in Early Stage Non-small Cell Lung Cancer
NCT04266691 ·Status: COMPLETED
-
Detection Cell Free DNA in Lung Cancer Patients
NCT02738593 ·Status: UNKNOWN
-
Study of CT and MR in the Lung Cancer
NCT04034667 ·Status: UNKNOWN
-
Biomarkers of Stage III Locally Advanced Unresectable Non-small-cell Lung Cancer
NCT04749407 ·Status: UNKNOWN
-
Comparison of Gene Mutations in Matched Samples in Advanced Nonsquamous NSCLC Using NGS
NCT02416726 ·Status: COMPLETED ·Phase: NA
-
Analysis of Plasma Tumor DNA in Lung Cancer Patients
NCT01930474 ·Status: UNKNOWN
-
A Prospective Epidemiologic Study of ALK-Positive NSCLC in China
NCT02042105 ·Status: COMPLETED
-
cfDNA Methylation Assay for Clinical Evaluation of Patients With Stage IA Lung Cancer After Ablation Operation
NCT04413656 ·Status: UNKNOWN ·Phase: NA
-
Study of Tumor Samples From Patients With Lung Cancer
NCT00900328 ·Status: COMPLETED
-
Exploration on the Value of MRD Based on ctDNA Detection in Predicting Recurrence of Resected Non-small Cell Lung Cancer
NCT05965024 ·Status: RECRUITING
-
Monitoring of Circulating Tumor DNA and Its Aberrant Methylation in the Surveillance of Surgical Lung Cancer Patients (MEDAL, MEthylation Based Dynamic Analysis for Lung Cancer).
NCT03634826 ·Status: UNKNOWN
-
Research of the EML4-ALK Gene Expression in the Pleural Effusion or Tumor Tissue From Lung Cancer Patients
NCT01257308 ·Status: UNKNOWN
-
Effects of Different Genetic Mutations on Prognosis in sMPLC Adenocarcinoma Patients
NCT03764371 ·Status: UNKNOWN
-
Circulating Tumor DNA in Surgical Lung Cancer Patients
NCT03081741 ·Status: UNKNOWN
-
Biomarker Discovery in Lung Cancer - Malaysia
NCT06504927 ·Status: RECRUITING
-
Novel Detection System for Lung Cancer Curative Effect Monitoring
NCT02666755 ·Status: UNKNOWN
-
Biomarkers for Diagnosis of Lung Cancer
NCT02050100 ·Status: COMPLETED
-
Multicenter Observational Study of Chinese Non-Small Cell Lung Cancer (NSCLC) Patients With Rare Driver Gene Mutation
NCT04137718 ·Status: UNKNOWN
-
Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated NSCLC Patients
NCT04566432 ·Status: RECRUITING
-
A Real-world Study to Explore Recurrence/Metastases of the NSCLC Patients and the Impact Factors of Patient Survivals
NCT03710616 ·Status: UNKNOWN
-
A Multi-center Prospective Observational Biomarker Study on EGFRm+ Non-small Cell Lung Cancer Patients With Leptomeningeal Metastasis
NCT02803619 ·Status: UNKNOWN
-
Significance of MRD Monitoring in Patients With Potentially Resectable Stage III Non-small Cell Lung Cancer
NCT06081777 ·Status: RECRUITING